Currently, there are 217.98M common shares owned by the public and among those 177.52M shares have been available to trade.
The company’s stock has a 5-day price change of 29.46% and 19.91% over the past three months. OSCR shares are trading 25.89% year to date (YTD), with the 12-month market performance down to -23.72% lower. It has a 12-month low price of $11.20 and touched a high of $23.79 over the same period. OSCR has an average intraday trading volume of 5.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.24%, 24.42%, and 6.23% respectively.
Institutional ownership of Oscar Health Inc (NYSE: OSCR) shares accounts for 64.67% of the company’s 217.98M shares outstanding.
It has a market capitalization of $4.31B and a beta (3y monthly) value of 1.83. The stock’s trailing 12-month PE ratio is 60.73, while the earnings-per-share (ttm) stands at $0.28. The company has a PEG of 0.38 and the debt-to-equity ratio at 0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.99% over the week and 5.49% over the month.
Analysts forecast that Oscar Health Inc (OSCR) will achieve an EPS of 0.48 for the current quarter, -0.14 for the next quarter and 1.09 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.39 while analysts give the company a high EPS estimate of 0.39. Comparatively, EPS for the current quarter was 0.2 a year ago. Earnings per share for the fiscal year are expected to increase by 647.86%, and 28.59% over the next financial year.
Looking at the support for the OSCR, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on March 13, 2025, with the firm’s price target at $20-$16. Jefferies coverage for the Oscar Health Inc (OSCR) stock in a research note released on December 10, 2024 offered a Underperform rating with a price target of $12. BofA Securities was of a view on November 06, 2024 that the stock is Underperform, while UBS gave the stock Neutral rating on October 07, 2024, issuing a price target of $23. Piper Sandler on their part issued Overweight rating on June 26, 2024.
